GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (NAS:ARWR) » Definitions » Piotroski F-Score

ARWR (Arrowhead Pharmaceuticals) Piotroski F-Score : 4 (As of Jul. 24, 2025)


View and export this data going back to 1995. Start your Free Trial

What is Arrowhead Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Arrowhead Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Arrowhead Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

ARWR' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 6
Current: 4

During the past 13 years, the highest Piotroski F-Score of Arrowhead Pharmaceuticals was 6. The lowest was 1. And the median was 3.


Arrowhead Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Arrowhead Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals Piotroski F-Score Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 4.00 4.00 3.00 2.00

Arrowhead Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 1.00 2.00 2.00 4.00

Competitive Comparison of Arrowhead Pharmaceuticals's Piotroski F-Score

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Net Income was -170.793 + -170.536 + -173.085 + 370.445 = $-144.0 Mil.
Cash Flow from Operations was -115.418 + -137.216 + -146.272 + 460.053 = $61.1 Mil.
Revenue was 0 + 0 + 2.5 + 542.709 = $545.2 Mil.
Gross Profit was 0 + 0 + 2.5 + 542.709 = $545.2 Mil.
Average Total Assets from the begining of this year (Mar24)
to the end of this year (Mar25) was
(955.15 + 883.759 + 1139.802 + 1013.694 + 1573.498) / 5 = $1113.1806 Mil.
Total Assets at the begining of this year (Mar24) was $955.2 Mil.
Long-Term Debt & Capital Lease Obligation was $316.5 Mil.
Total Current Assets was $1,135.2 Mil.
Total Current Liabilities was $220.5 Mil.
Net Income was -102.946 + -109.679 + -132.864 + -125.3 = $-470.8 Mil.

Revenue was 15.825 + 16.097 + 3.551 + 0 = $35.5 Mil.
Gross Profit was 15.825 + 16.097 + 3.551 + 0 = $35.5 Mil.
Average Total Assets from the begining of last year (Mar23)
to the end of last year (Mar24) was
(891.308 + 795.856 + 765.552 + 626.286 + 955.15) / 5 = $806.8304 Mil.
Total Assets at the begining of last year (Mar23) was $891.3 Mil.
Long-Term Debt & Capital Lease Obligation was $113.6 Mil.
Total Current Assets was $541.7 Mil.
Total Current Liabilities was $65.2 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Arrowhead Pharmaceuticals's current Net Income (TTM) was -144.0. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Arrowhead Pharmaceuticals's current Cash Flow from Operations (TTM) was 61.1. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar24)
=-143.969/955.15
=-0.1507292

ROA (Last Year)=Net Income/Total Assets (Mar23)
=-470.789/891.308
=-0.52820013

Arrowhead Pharmaceuticals's return on assets of this year was -0.1507292. Arrowhead Pharmaceuticals's return on assets of last year was -0.52820013. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Arrowhead Pharmaceuticals's current Net Income (TTM) was -144.0. Arrowhead Pharmaceuticals's current Cash Flow from Operations (TTM) was 61.1. ==> 61.1 > -144.0 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=316.456/1113.1806
=0.28428092

Gearing (Last Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=113.632/806.8304
=0.14083753

Arrowhead Pharmaceuticals's gearing of this year was 0.28428092. Arrowhead Pharmaceuticals's gearing of last year was 0.14083753. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar25)=Total Current Assets/Total Current Liabilities
=1135.22/220.541
=5.1474329

Current Ratio (Last Year: Mar24)=Total Current Assets/Total Current Liabilities
=541.65/65.175
=8.31070196

Arrowhead Pharmaceuticals's current ratio of this year was 5.1474329. Arrowhead Pharmaceuticals's current ratio of last year was 8.31070196. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Arrowhead Pharmaceuticals's number of shares in issue this year was 134.484. Arrowhead Pharmaceuticals's number of shares in issue last year was 123.285. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=545.209/545.209
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=35.473/35.473
=1

Arrowhead Pharmaceuticals's gross margin of this year was 1. Arrowhead Pharmaceuticals's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar24)
=545.209/955.15
=0.57080982

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar23)
=35.473/891.308
=0.03979881

Arrowhead Pharmaceuticals's asset turnover of this year was 0.57080982. Arrowhead Pharmaceuticals's asset turnover of last year was 0.03979881. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+0+0+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Arrowhead Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Arrowhead Pharmaceuticals  (NAS:ARWR) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Arrowhead Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Arrowhead Pharmaceuticals Business Description

Traded in Other Exchanges
Address
177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Executives
Christopher Richard Anzalone director, officer: President and CEO ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Adeoye Y Olukotun director 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Kenneth Allen Myszkowski officer: CFO ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Patrick O'brien officer: General Counsel 225 S. LAKE AVENUE SUITE 1050, PASADENA CA 91101
James C Hamilton other: Senior Vice President 177 EAST COLORADO BLVD, SUITE 700, PASADENA CA 91105
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Douglas B Given director C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Victoria Vakiener director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Tracie Oliver officer: Chief Commercial Officer 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Mauro Ferrari director 201 SOUTH LAKE AVENUE, PASADENA CA 91101
Martin Javier San officer: Chief Medical Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Michael S Perry director C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Backer Marianne De director 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
James Hassard officer: Chief Commercial Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Curt Bradshaw officer: Chief Scientific Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105